CYTOKINETICS INC 4

Cytokinetics President & CEO Robert I. Blum exercised 7,490 options and sold 7,500 Cytokinetics (CYTK) common shares on July 13, 2026, for about $615K in total value while maintaining a large remaining stake.

On July 13, 2026, Cytokinetics Inc. President & CEO Robert I. Blum exercised 7,490 non-qualified stock options at $10.60 per share and immediately sold the same 7,490 shares at $82.02 per share, while also selling an additional 10 shares of common stock at $82.02. The option exercise was priced at zero in the Form 4 transaction table (reflecting no cash paid at that step) but references an underlying option grant with a $10.60 exercise price originally granted on March 28, 2017 and expiring February 28, 2027. After these transactions, Blum’s directly held common stock position remained 377,820 shares, with an additional 2,083 shares held indirectly in each of two separate 2003 irrevocable trusts (the Bridget Blum and Brittany Blum trusts). Using the reported sale price of $82.02 to approximate value, the direct sales totaled roughly $614,600, while his remaining directly held shares are worth approximately $31 million, indicating this was a relatively small liquidity transaction compared with his overall ownership stake.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000077

Alert Tier

6